CA
ATOS icon

Clearstead Advisors’s Atossa Therapeutics ATOS Stock Holding History

Clearstead Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Hold
4
– – ﹤0.01% 3627
2026
Q1 		$22 Sell
4
-1
-20% -$6 ﹤0.01% 2218
2025
Q4 		$42 Hold
5
– – ﹤0.01% 2625
2025
Q3 		$61 Hold
5
– – ﹤0.01% 2962
2025
Q2 		$59 Hold
5
– – ﹤0.01% 2659
2025
Q1 		$48 Hold
5
– – ﹤0.01% 2162
2024
Q4 		$67 Hold
5
– – ﹤0.01% 2056
2024
Q3 		$107 Hold
5
– – ﹤0.01% 1996
2024
Q2 		$84 Hold
5
– – ﹤0.01% 1990
2024
Q1 		$103 Hold
5
– – ﹤0.01% 1504
2023
Q4 		$62 Hold
5
– – ﹤0.01% 1502
2023
Q3 		$52 Hold
5
– – ﹤0.01% 1461
2023
Q2 		$89 Buy
+5
New +$61 ﹤0.01% 1354

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clearstead Advisors's ATOS Position: Q2 2026 in Review

Clearstead Advisors held its Atossa Therapeutics (ATOS) position steady in Q2 2026 at 4 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #3627.

Clearstead Advisors first reported a position in ATOS in Q2 2023 and has held it in 13 quarters since. The position peaked at $107 in Q3 2024. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Clearstead Advisors held 4 shares of Atossa Therapeutics worth $8 as of Q2 2026.
  • Clearstead Advisors left its Atossa Therapeutics share count unchanged in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3627 holding.
  • Clearstead Advisors first reported a position in Atossa Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Clearstead Advisors's Atossa Therapeutics position peaked at $107 in Q3 2024.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.